Skip to content

The Evaluation of a Mobile Device to Measure Ataxia With High Altitude Exposure

The Evaluation of a Mobile Device to Measure Ataxia With High Altitude Exposure

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02600078
Enrollment
16
Registered
2015-11-09
Start date
2015-11-30
Completion date
2016-12-31
Last updated
2020-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxia

Keywords

hypoxia, ataxia

Brief summary

With exposure to high altitude some individuals will develop acute mountain sickness (AMS). Current evaluation of AMS can make it difficult to rule out other possible conditions. Evaluation of ataxia, as measured by the performance of a coordinated task, can aide in the correct diagnosis of AMS. The investigators have developed novel finger-tapping tasks on a mobile device to assess both reaction time and accuracy. The proposed research will evaluate the utility of this tool in assessing human acclimatization to hypoxia.

Detailed description

Introduction: Hypoxia is the reduction in partial pressure of oxygen that occurs with exposure to altitude. Individuals acclimatize at different rates and to different degrees meaning that those who are slow to make the necessary physiological adjustments will develop signs and symptoms of acute mountain sickness (AMS). AMS is marked by headache, gastrointestinal disturbances, insomnia, fatigue and ataxia, which can be evaluated using subjective questionnaires such as the Lake Louise Score (LLS). Evaluation of AMS by solely using subjective questionnaires can make differential diagnosis of other possible pathologies difficult. Ataxia is characterized by poor coordination in the absence of significant weakness. Ataxia can be assessed with the performance of a coordinated task. The investigators have developed a novel finger-tapping task on a mobile device to assess both reaction time and accuracy. The proposed research will evaluate the utility of this tool in assessing human acclimatization to hypoxia, which could ultimately serve as a novel, objective methodology in the diagnosis of AMS. Hypothesis: (1) When exposed to simulated altitude (equivalent to 4200m above sea level), subjects will exhibit diminished coordination relative to a sham exposure. (2) Reaction time of novel coordination tasks will positively correlate with heart rate, balance, and LLS. (3) Accuracy of novel coordination tasks will negatively correlate with heart rate, balance, and LLS. Methods: A repeated-measures design with a familiarization trial, a hypoxic trial, and a sham trial will be used. Sixteen healthy adults will be exposed to normobaric hypoxia in the investigator's chamber, simulating an elevation of 4200m above sea level. Subjects will be measured for pulse oxygen saturation, heart rate, and will complete the LLS, the Balance Error Scoring System (BESS), as well as two electronic finger tap coordination tasks prior to, and at 5 minutes, 4, and 12 hours into the altitude chamber exposure. Outcomes: This research will enhance the investigators understanding of the relationship between coordination, balance, and acclimatization to hypoxia. It will allow us to validate a new objective tool in the measurement of acclimatization with exposure to hypoxia.

Interventions

DEVICEAMS Monitor App

Participants will complete a novel coordination task performed on an android phone.

OTHERLake Louise Score

Participants will complete a questionnaire to assess acclimatization to hypoxia.

OTHERBalance Error Scoring System

Participants will complete a series of static stance positions to evaluate their ability to maintain balance.

OTHERHeart Rate & Pulse Oxygen Saturation

Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.

Sponsors

British Columbia Sports Medicine Research Foundation
CollaboratorOTHER
University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Both Male and Female Gender * Minimum Age of 18 years * Maximum Age of 45 years * Have not traveled to an altitude of 3000m or higher in 3 months prior to testing * No history of migraines or concussion * Not Smokers * Females must be using monophasic birth control * Not easily claustrophobic * English Speaking

Exclusion criteria

* Non-English speaking individuals * Subjects younger than 18 years old or older than 45 years old * Subjects who visit an altitude of 3000m or greater within three months prior to the study * Subjects with a history of cardiovascular or pulmonary conditions such as; uncontrolled congestive heart failure, COPD, pulmonary hypertension, or sickle cell disease * Subjects with a history of migraines or concussion * Smokers * Females not using monophasic birth control pills * Subjects experiencing withdrawal symptoms due to abstinence from caffeine * Easily claustrophobic individuals

Design outcomes

Primary

MeasureTime frame
Change in score of a coordination test.Coordination test will be taken at baseline and at 5 minutes, 4 and 12 hours into a simulated altitude exposure.

Secondary

MeasureTime frame
Change in severity of symptoms based on questionnaire.Symptoms questionnaire will be assessed at baseline and at 5 minutes, 4 and 12 hours into a simulated altitude exposure.
Change in score of a balance test.Balance test will be taken at baseline and at 5 minutes, 4 and 12 hours into a simulated altitude exposure.
Change in heart rate.Heart rate will be assessed at baseline and at 5 minutes, 4 and 12 hours into a simulated altitude exposure.
Change in pulse oxygen saturationPulse oxygen saturation will be assessed at baseline and at 5 minutes, 4 and 12 hours into a simulated altitude exposure.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026